| What it is | Combination of circadian-effective blue light (narrowband) and rhythmic light therapy (40 Hz visual flicker), both designed for at-home or facility use. | Circadian-effective blue light (narrowband), with placebo rhythm (random flicker), providing light exposure without the rhythmic stimulation. | Red (placebo) light, combined with the investigational rhythmic visual stimulation at 40 Hz. | Red (placebo) light with placebo (random) rhythm, serving as the double-placebo control group. |
|---|
| Role in the study | Evaluates the combined effect of both circadian-effective blue light exposure and rhythmic 40 Hz flicker for potential cognitive and sleep benefits. | Assesses the effect of blue light alone, controlling for rhythm/flicker. | Isolates the effect of rhythmic 40 Hz flicker apart from any blue light exposure. | Controls for placebo effects, without active blue light or therapeutic rhythm. |
|---|
| Primary intended use | Investigational therapy for mild cognitive impairment and mild Alzheimer's disease, aiming to improve cognition and sleep quality. | Assesses whether blue light exposure alone can improve cognition or sleep compared to other combinations. | Assesses whether rhythmic flicker alone can benefit cognition or sleep in this population. | Provides a baseline measure of cognition and sleep changes with placebo interventions. |
|---|
| How it is given or performed | Participants receive scheduled daily sessions of blue circadian-effective light with synchronous 40 Hz rhythmic flicker at home or in assisted/independent living. | Participants use blue circadian-effective light with sham (random) flicker at home or in facility. | Participants use red placebo light with therapeutic 40 Hz flicker at their residence or facility. | Participants receive red placebo light and random (non-40 Hz) sham flicker, mirroring active intervention schedule. |
|---|
| Evidence status / maturity | Currently under investigation; efficacy and safety are not yet established from this randomized trial. | Efficacy for blue light alone is investigational; results from this and other arms will clarify independent effects. | The effect of rhythmic visual flicker alone on cognition or sleep is investigational; results are pending. | Represents placebo-controlled baseline in the study; no expected clinical effect beyond placebo response. |
|---|
| Important limitations | Long-term cognitive and sleep effects are unknown; protocol excludes individuals with severe visual, sleep, or neurological disorders. | Findings may not generalize beyond selected population; effects specific to light exposure without rhythmic flicker are not yet clear. | Unknown whether rhythmic 40 Hz flicker provides clinical benefit; restricted to those without severe visual or sleep disorders. | Placebo control group findings are limited to benchmarking for active interventions; no therapeutic light or rhythm is used. |
|---|